Optimizing laser treatment for open angle glaucoma
Efficacy of Selective Laser Trabeculoplasty Targeting Nasal Versus Inferior 180-degree
This study is testing whether different ways of using laser treatment can better lower eye pressure in people with open-angle glaucoma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 102 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 2 sites (Rochester, Minnesota and 1 other locations) |
| Trial ID | NCT06851546 on ClinicalTrials.gov |
What this trial studies
This research aims to determine the most effective method of using Selective Laser Trabeculoplasty (SLT) to lower intraocular pressure in patients with open-angle glaucoma. The study will compare the efficacy of nasal versus inferior 180-degree SLT applications. Additionally, it will evaluate the effects of repeating SLT in the opposite sector after three months. The goal is to enhance treatment outcomes for patients suffering from ocular hypertension or glaucoma.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with open-angle glaucoma or ocular hypertension who have not achieved adequate intraocular pressure control.
Not a fit: Patients who have previously undergone laser treatment or intraocular surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of intraocular pressure in patients with open-angle glaucoma, potentially preserving vision.
How similar studies have performed: Other studies have explored SLT techniques, but this specific comparison of nasal versus inferior 180-degree SLT is a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years and older * Ability to comprehend the study procedures and agreement to proceed with primary SLT treatment * Diagnosis of primary or secondary open angle glaucoma or glaucoma suspects with ocular hypertension * Bilateral disease * Pre-SLT IOP \>21 mmHg measured at least twice during patient's lifetime with or without medication * Open angles with moderate to intense trabecular pigmentation * Mild to moderate visual field defects (24-2 standard mean deviations better than the Swedish interactive thresholding algorithm standard of 12 dB) * No adequate IOP control (low treatment compliance, substantial adverse effects with eyedrops, and at least 2 IOP measurements higher than the individualized target IOP) Exclusion Criteria: * Unwilling or unable to give consent * Unable to attend scheduled post-operative visits * Previous history of either laser treatment or intraocular surgery, except for non-complicated cataract surgery (performed \>6 months before SLT) * History of ocular trauma * Narrow angles * Retinal detachment * Active iris neovascularization or active proliferative retinopathy * Active uveitis * Monocular patients * Current use of steroids (ocular, periocular, or systemic)
Where this trial is running
Rochester, Minnesota and 1 other locations
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (Recruiting)
- Eye Care Centre, Victoria General Hospital — Halifax, Nova Scotia, Canada (Recruiting)
Study contacts
- Principal investigator: Arthur Sit — Mayo Clinic
- Study coordinator: Rami Darwich, MD, PhD
- Email: Darwich.Rami@mayo.edu
- Phone: 507-284-2787
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.